P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY
Won-Seog Kim(Samsung Medical Center), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Eva Domingo‐Doménech, Andre Overesch(Affimed Therapeutics (Germany)), Kerstin Pietzko(Affimed Therapeutics (Germany)), Karenza Alexis(American Foundation for Suicide Prevention), Vincent Ribrag(Institut Gustave Roussy), Ana Marín‐Niebla(Vall d'Hebron Hospital Universitari), Michael Emig(Affimed Therapeutics (Germany)), Dejan Radeski(Sir Charles Gairdner Hospital), Linta Garcia(American Foundation for Suicide Prevention), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), N. M. Mikhaylova(First Pavlov State Medical University of St. Petersburg), Jake Shortt(The University of Melbourne), Ahmed Sawas(Columbia University Irving Medical Center)
Cited by 4
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|Journal of Clinical Oncology|2015|418